Medpace Inc., a global leader in clinical trial management, is pleased to announce support for the completion of a project to revitalize property located near its headquarters in Madisonville. The property, located at the intersection of Red Bank and Madison roads, is owned by developer RBM Development, LLC, which is not affiliated with Medpace. Redevelopment of the site, situated on 29 acres near I-71 and Duck Creek Road, began with completion of the Medpace corporate campus in 2012.
RBM proposes to complete the development of the site with its vision of a welcoming gateway to Madisonville, demonstrating that the historic community is vibrant and poised for future success. Medpace expects the project to serve as a catalyst for continued growth and renewal in the area that will be a boon to all residents of Madisonville. “As a stakeholder in this neighborhood, we are supportive of and see real benefits to the community from the road improvements related to the Duck Creek extension,” said Stephen Ewald, General Counsel of Medpace. “These road improvements will result in better access to and from I-71, easier access for our employees and customers to the Medpace campus, and easier access to the east side of Madisonville, including for students attending JP Parker Elementary. The Mayor of Cincinnati – John Cranley – and many others share the belief to act on this road extension.”
“I am committed to making sure that this small connector road gets built as soon as possible. I believe it is good for this congested intersection and good for Madisonville. As we finalize the details, we will continue to work with CPS and with the community,” said Cincinnati Mayor John Cranley.
Mr. Ewald added, “Our view is that continued development in Madisonville will go a long way to create opportunities and promote growth, including for the local schools.”
In keeping with this theme and mission, Medpace will soon be announcing a partnership with Cincinnati Public Schools that will include promoting and supporting learning experiences for students focused on educational programs at JP Parker Elementary School.
Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and 6 regions – the US, Europe, Central and Eastern Europe, India, Asia Pacific, and China. From feasibility, research site compatibility, safety, and logistics, Medpace brings innovative efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management. Our mission is to accelerate the global development of safe and effective medical therapeutics.